Details of Drug-Drug Interaction
| Drug General Information (ID: DDIUSVPI5C) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Eptifibatide | Drug Info | Choline salicylate | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Anticoagulants | Salicylates | |||||||
| Structure | |||||||||
| Mechanism of Eptifibatide-Choline salicylate Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of bleeding Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Eptifibatide | Choline salicylate | |||||||
| Mechanism |
Risk of bleeding Antiplatelet |
Risk of bleeding Antiplatelet effects |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Bleeding | ||||||||
| Factor Description | Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications. Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites. Therapy should be discontinued immediately if serious or uncontrollable bleeding or thrombocytopenia occurs. | ||||||||